Cerebrospinal fluid τ protein in differential diagnosis of alzheimer's disease and vascular dementia in chinese population: A meta-analysis

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 2, 2014, Pages 116-122

  Liu, Bo ^a   Tang, Yulan ^b   Shen, Yuefei ^b   Cen, Luan ^b   Han, Min ^a  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; cerebrospinal fluid; Chinese population; dementia; meta analysis; vascular dementia; protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CASE CONTROL STUDY; CEREBROSPINAL FLUID ANALYSIS; CHINESE; CLINICAL ASSESSMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; META ANALYSIS; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; ASIAN CONTINENTAL ANCESTRY GROUP; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); DEMENTIA, VASCULAR; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; TAU PROTEINS;

EID: 84898986718     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513507374     Document Type: Review

References (61)

1. Van Harten AC, Kester MI, Visser PJ, et al. Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med. 2011 ; 49 (3). 353-366
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005 ; 366 (9503). 2112-2117
3. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. 2007 ; 113 (4). 349-388
4. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc. 2003 ; 51 ((5 suppl dementia). S296 - S304
5. Boban M, Grbic K, Mladinov M, et al. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia. Coll Antropol. 2008 ; 32 (suppl 1). 31-36
6. Leszek J, Malyszczak K, Janicka B, Kiejna A, Wiak A. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. Med Sci Monit. 2003 ; 9 (11). CR484 - CR488
7. Skogseth RE, Fladby T, Mulugeta E, Aarsland D. Biomarkers in spinal fluid of patients with dementia. Tidsskr Nor Laegeforen. 2011 ; 131 (22). 2235-2238
8. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004 ; 61 (1). 95-102
9. Shan S, Zhao Q, Zhang L, Sun Y. Alzheimer's patients CSF protein tau and A beta 1 to 42. Chin J Nerv Ment Dis. 2011 ; 37 (11). 691-693
10. Liu X, Lu L, Chen Z. Alzheimer's patients CSF alpha-synuclein A beta 42 T-1-P-tau tau NF-L level change and significance. Shandong Med. 2013 ; 53 (3). 90-92
11. Wang K, Ding X, Cheng H, Zhang X, Yao J. Old age dementia patients with cerebrospinal fluid protein tau with various clinical indicators correlation studies. Chin J Clin Rehabil. 2002 ; 6: 3174-3175
12. Engelborghs S, Le Bastard N. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. J Neurol Sci. 2012 ; 322 (1-2). 197-199
13. Palmqvist S, Hertze J, Minthon L, et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. PLoS ONE. 2012 ; 7 (6). e38639
14. Jia J, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005 ; 383 (1-2). 12-16
15. Grundke-Iqbal I, Rolkova G, Konstekova E, Iqbal K. Biological markers in Alzheimer's disease. Bratisl Lek Listy. 2006 ; 107 (9-10). 359-365
16. Kurz A, Riemenschneider M, Wallin A. Potential biological markers for cerebrovascular disease. Int Psychogeriatr. 2003 ; 15 (suppl 1). 89-97
17. Bibl M, Mollenhauer B, Esselmann H, et al. Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord. 2008 ; 25 (3). 256-265
18. Wang L, Wang H, Guo D, Wang D, Han J. Cerebrospinal fluid in patients with Alzheimer disease Tau protein level of detection and its clinical significance. J Clin Neurol. 2002 ; 15 (6). 352-354
19. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001 ; 50 (2). 150-156
20. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. report of the NINDS-AIREN international workshop. Neurology. 1993 ; 43 (2). 250-260
21. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011 ; 11: 41
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-560
23. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007 ; 335 (7626). 914-916
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 ; 315 (7109). 629-634
25. Saltelli A. Sensitivity analysis for importance assessment. Risk Anal. 2002 ; 22 (3). 579-590
26. Ding X, Wang K, Cheng H, Shen X, Yao J, Deng XX. Old age dementia patients CSF tau protein detection and clinical research. Jiangsu Med J. 2000 ; 26 (3). 164-166
27. Hu Y, He S, Wang J. Cerebrospinal fluid protein tau content determination of value to the diagnosis of Alzheimer's disease. Chin Med J. 2001 ; 81 (22). 1377-1379
28. Kong F, Feng T, Zhang Y. Dementia and cerebrospinal fluid of Tau protein content. J Jilin Univ (Med Ed). 2002 ; 28 (5). 511-514
29. Li L, Li T, Li C, Tu R. Tau protein and apolipoprotein E value to the diagnosis of dementia. Chin Gen Pract. 2002 ; 5 (11). 871-872
30. Wan Y. Determination of Tau protein in cerebrospinal fluid and at the same time A beta 1 to 42 content on the significance of diagnosis of Alzheimer's disease. Chin J Neurosci. 2003 ; 19 (1). 41-44
31. Cheng H, Ding X, Zhang X, Wang K, Yao J. Tau protein in cerebrospinal fluid and A beta test significance in early diagnosis of dementia in old age. J Nanjing Med Univ (Nat Sci Ed). 2004 ; 24 (1). 69-71
32. Li Y, Zhang Z, Lv L, Hao W, Ding X. Alzheimer's disease and vascular dementia in patients with cerebrospinal fluid protein tau and beta-amyloid 1-42 concentration control study. Chin J Psychiatry. 2004 ; 37 (4). 220-223
33. Liu J, Pan J, Zhu J, Li A. A beta 1 to 42 tau protein in cerebrospinal fluid and IL-6 in the test in the diagnosis of Alzheimer's disease. J Clin Lab Sci. 2004 ; 22 (5). 383
34. Xie H, Xiao S, Sun Y, Zhang M. Cerebrospinal fluid biological markers in diagnosis of Alzheimer's disease and vascular dementia. Chin J Modern Neural Dis. 2007 ; 7 (3). 257-261
35. Yu J, Yin J, Liu H, Liu X, Shen H. Cerebrospinal fluid protein Tau and beta-amyloid serum concentrations of AD VD patients in the early stages of a controlled study. Cardio-cerebrovascular disease prevention and control.. 2009 ; 9 (2). 128-130
36. Fang Y. Cerebrospinal fluid phosphorylated tau protein and amyloid beta testing for early differential diagnosis of patients with dementia in old age. Chin J Gerontol. 2011 ; 31 (13). 2561-2562
37. Kalback W, Esh C, Castaño EM, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res. 2004 ; 26 (5). 525-539
38. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol. 2008 ; 585 (1). 119-129
39. Humpel C, Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease. Curr Neurovasc Res. 2005 ; 2 (4). 341-347
40. Zhu X, Smith MA, Honda K, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci. 2007 ; 257 (1-2). 240-246
41. Paraskevas GP, Kapaki E, Papageorgiou SG, et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol. 2009 ; 16 (2). 205-211
42. Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen J. H. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: A review of recent literature. Curr Clin Pharmacol. 2008 ; 3 (2). 123-131
43. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging. 2007 ; 28 (1). 1-7
44. Ravaglia S, Bini P, Sinforiani E, et al. Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci. 2008 ; 29 (6). 417-423
45. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int. 2011 ; 58 (4). 458-471
46. Gong CX, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer's disease. Drugs Aging. 2010 ; 27 (5). 351-365
47. Paraskevas GP, Kapaki E, Liappas I, et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol. 2005 ; 18 (3). 163-173
48. Stefani A, Bernardini S, Panella M, et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci. 2005 ; 237 (1-2). 83-88
49. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 ; 61 (5). 1828-1834
50. Vigo-Pelfrey C, Barbour R, Blomquist C, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995 ; 45 (4). 788-793
51. Paradowski B, Jaremko M, Dobosz T, Leszek J, Noga L.. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol. 2007 ; 254 (2). 154-159
52. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2012 ; 6 (4). 455-476
53. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007 ; 14 (1). e1 - e26
54. Smach MA, Charfeddine B, Lammouchi T, et al. Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease. Ann Biol Clin (Paris). 2008 ; 66 (5). 531-535
55. Thaweepoksomboon J, Senanarong V, Poungvarin N, et al. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai. 2011 ; 94 (suppl 1). S77-83
56. Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012 ; 78 (1). 47-54
57. Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am. 2013 ; 97 (3). 369-376
58. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010 ; 9 (7). 560-574
59. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: A review. Int J Geriatr Psychiatry. 2011 ; 26 (10). 991-999
60. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006 ; 355 (25). 2652-2663
61. Roman G, Pascual B. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia. Arch Med Res. 2012 ; 43 (8). 671-676